Daily Stock Analysis, IONS, Ionis Pharmaceuticals Inc, priceseries

Ionis Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
55.53
Close
57.06
High
57.53
Low
55.01
Previous Close
55.35
Daily Price Gain
1.71
YTD High
86.58
YTD High Date
Apr 8, 2019
YTD Low
52.45
YTD Low Date
Jan 2, 2019
YTD Price Change
3.29
YTD Gain
6.12%
52 Week High
86.58
52 Week High Date
Apr 8, 2019
52 Week Low
48.27
52 Week Low Date
Dec 24, 2018
52 Week Price Change
5.56
52 Week Gain
10.80%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 12. 2017
39.35
May 8. 2017
46.28
17 Trading Days
17.61%
Link
LONG
Aug 30. 2017
50.99
Sep 20. 2017
54.20
14 Trading Days
6.30%
Link
LONG
Oct 4. 2017
54.31
Oct 24. 2017
58.14
14 Trading Days
7.05%
Link
LONG
Aug 8. 2018
45.57
Aug 24. 2018
49.95
12 Trading Days
9.62%
Link
LONG
Sep 14. 2018
46.00
Oct 1. 2018
50.33
11 Trading Days
9.42%
Link
LONG
Oct 30. 2018
49.06
Nov 9. 2018
51.59
8 Trading Days
5.16%
Link
LONG
Jan 4. 2019
54.33
Jan 24. 2019
57.12
13 Trading Days
5.14%
Link
LONG
Mar 7. 2019
69.81
Mar 27. 2019
76.78
14 Trading Days
9.99%
Link
Company Information
Stock Symbol
IONS
Exchange
NasdaqGS
Company URL
http://www.ionispharm.com
Company Phone
7609319200
CEO
Stanley T. Crooke
Headquarters
California
Business Address
2855 GAZELLE COURT, CARLSBAD, CA 92010
Sector
-
Industry Category
-
Industry Group
-
CIK
0000874015
About

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of antisense drug discovery. It operates its business through the Ionis Core and Akea Therapeutics segments. The Ionis Core segment involves a a novel drug discovery platform generate a broad pipeline of drugs. The Akea Therapeutics segment develops and commercializes drugs for cardiometabolic disorders. The company was founded by Stanley T. Crooke in January 1989 and is headquartered in Carlsbad, CA.

Description

Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company's flagship product includes the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with...